Back to results

University of Texas Health Science Center at Houston

Leveraging Single Cell Technologies For The Characterization and Treatment of Refractory Pancreatic Cancer

Abstract

dc:description.abstract

<p>Heterogeneity is a hallmark of cancer, and the advent of multimodal single-cell technologies has helped uncover heterogeneity in a high-throughput manner in different cancers across varied contexts at an unprecedented resolution. In an effort to improve precision medicine approaches in pancreatic ductal adenocarcinoma (PDAC), a highly lethal malignancy with a mere 11% 5-year survival rate, this dissertation focuses on first questioning the assumptions of the most basic models used to study PDAC via multimodal single-cell characterization methods at multiple levels of biological organization (scCNVseq and snATACseq for DNA assays, scRNAseq for transcriptomics, and paired protein assays such as multiplexed immunofluorescence and fluorescence in situ hybridization for validation methods) to reveal inherent heterogeneity in assumptively isogenic pancreatic cancer (PDAC) cell lines, patient-derived organoids (PDOs), and patient tissue samples that contribute to the proliferation of resistant cell phenotypes and, ultimately, treatment failures in the clinic. I then apply single-cell characterization methods to a panel of PDO samples to explore adaptive resistance mechanisms of PDAC lesions following administration of epigenetically-modifying therapeutic agents (HDAC inhibitors). I describe a novel HDACi resistance mechanism of AP1 activation, which can be intercepted by using an AP1 inhibitor in combination with an HDAC inhibitor to achieve tumor cell death. Finally, in an effort to explore and characterize the molecular consequences of newly-developed KRAS inhibitors in PDAC samples, I present a series to studies illustrating differential PDO sensitivity to KRAS inhibitors with different mechanisms of action, induce KRASi-resistance in select G12C-mutant PDO samples, and suggest avenues for future study to achieve maximal clinical benefit for PDAC patients on KRAS-inhibitory therapies.</p>

Degree

thesis:*
Name thesis:degree_name
Doctor of Philosophy (PhD)
Level thesis:degree_level
Dissertation (PhD)
Year dc:date.available
2022

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Monberg, Maria
  • https://orcid.org/ <p><strong>0000-0002-5643-0232</strong></p>
Contributors dc:contributor
  • Anirban Maitra
  • Cullen Taniguchi
  • Ken Chen

Subjects

dc:subject × 7

Identifiers

dc:identifier.*
OAI identifier oai:identifier
oai:digitalcommons.library.tmc.edu:utgsbs_dissertations-2252

Chain of custody

source
Harvested from
University of Texas Health Science Center at Houston
Base URL
digitalcommons.library.tmc.edu/do/oai/
Last updated
2026-07-24
Source record
OAI-PMH GetRecord
citation

Monberg, Maria; https://orcid.org/ <p><strong>0000-0002-5643-0232</strong></p>. Leveraging Single Cell Technologies For The Characterization and Treatment of Refractory Pancreatic Cancer. Dissertation (PhD) thesis, 2022. https://digitalcommons.library.tmc.edu/utgsbs_dissertations/1195